Celgene rolls along with another epigenetic preclinical deal featuring a Canadian biotech
In another declaration of its ongoing commitment to dealmaking, Celgene is turning to longtime partners at Triphase Accelerator for its latest preclinical asset.
The area in focus this time? Epigenetics.
Specifically, the drug that Celgene has just paid $40 million for targets the WDR5 protein, which is deemed critical for the formation and DNA-regulating activities of MLL1-associated methylation complexes. They believe it’s a first-in-class candidate holding promise in a range of blood cancers, including acute lymphoblastic leukemia and acute myeloid leukemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.